is to determine whether the favourable effects of inhibition of the sodium glucose co-transporter 2 (SGLT2) on blood glucose, blood pressure and body weight are accompanied by protection against adverse renal outcomes.
| MATERIALS AND METHODS

CANVAS-R is
| Participant inclusion and exclusion criteria
Participants in the CANVAS-R trial are men and women with T2DM who had inadequate glycaemic control at baseline (glycated haemoglobin
[HbA1c] ≥7.0% and ≤10.5%) and have a history or are at an elevated risk of cardiovascular disease. All participants were required to provide informed consent, to be willing and able to adhere to the study protocol and to successfully complete the trial's placebo run-in period. To ensure the recruitment of a broad population group, there were minimal restrictions on the use of background therapies for glucose control or cardiovascular risk factor management. The inclusion criteria were designed to be identical to the twinned CANVAS study and were powered to achieve an event rate of ≥2.25% per year 11 for the cardiovascular outcome (cardiovascular death, myocardial infarction or stroke) so that the data can be seamlessly integrated with data from CANVAS to address safety, as stipulated by the US Food and Drug Administration (FDA), and efficacy. 
| Screening and run-in
All potential participants completed a 2-week, single-blind, placebo run-in period if screening criteria were met. If eligibility was confirmed, the participant was counselled about diet and exercise, trained in the recognition of hypoglycaemia, provided with materials for making selfmonitored blood glucose measurements and then provided with singleblind placebo therapy. The primary purpose of the run-in period was to exclude individuals who were unlikely to adhere to the long-term treatment and follow-up regimen required by the trial.
| Randomization
Randomization was carried out centrally through an interactive web response system. Participants were randomly assigned in a 1:1 ratio to canagliflozin or matching placebo on the basis of a computergenerated randomization schedule that was prepared by the study sponsor using randomly permuted blocks.
| Post-randomization study treatment and control
Study treatment is provided in identical bottles for both canagliflozin and matching placebo. Canagliflozin was administered at an initial dose of 100 mg daily but, at week 13 (or any time thereafter), the dose of canagliflozin (or matching placebo) may be increased from 100 to 300 mg. Uptitration is encouraged if the participant requires additional glycaemic control (eg, if ≥50% of glucose measurements from fasting fingerstick readings exceeded 6 mmol/L [110 mg/dL] during the 2 weeks preceding) and there has been no hypoglycaemia, volume depletion or other adverse event that might preclude dose increase. Participants are instructed to take the study treatment once daily before the first meal of the day until completion of the study or premature treatment discontinuation. Participants and all study staff will be masked to individual treatment allocation until the completion of the study.
| Background drug treatments
Use of SGLT2 inhibitors is precluded, but participants are otherwise free to use other background therapy for glycaemic management at the discretion of the responsible investigator, in line with applicable local guidelines. Likewise, the use of all other therapies, particularly for cardiovascular and renal risk factors, will be according to best practice throughout the course of the study, instituted according to local guidelines and policies.
| Follow-up schedule
Post-randomization, face-to-face follow-up is scheduled for 13 and 26 weeks after randomization and at 6-month intervals thereafter. Additionally, telephone follow-up is scheduled at 6 weeks, 9 months and every 6 months thereafter, such that it alternates with the face-to-face visits. Every follow-up contact includes an inquiry about adverse events and concomitant therapies. All face-to-face visits also include provision of study medication and recording of physical measurements. First morning urinary ACR and serum creatinine levels are measured every 6 months.
After the year 1 visit, clinical laboratory assessments are performed every 6 or 12 months. Individuals who prematurely discontinue study treatment are encouraged to return for regular assessments to ensure full ascertainment of study outcomes and to support an intention-to-treat analysis for all outcomes. Patient retention is supported by flexibility in the follow-up regimen such that investigators can schedule additional visits or reduce the intensity of follow-up as required. Further, the consent process included agreement by the participant for the investigator to consult family members, the participant's physicians, medical records or public records in the event they are not reachable by conventional means.
| Outcomes
The primary outcome is progression of albuminuria, which is defined as a change from normoalbuminuria to microalbuminuria or macroalbuminuria, or from microalbuminuria to macroalbuminuria, accompanied by an ACR value increase of ≥30% from baseline. The main analysis will be on incident events, with a supplementary analysis carried out that is restricted to events with duplicate measures of progressions in which a repeat ACR collection was carried out~1 to 2 months later to identify sustained progression of albuminuria. In the circumstance where the last recorded ACR value meets the definition of progression, it will be deemed to be a sustained progression for the subsidiary analysis. ACR assessments will be based on values obtained from duplicate first morning void urines and analysed by a central laboratory. The secondary outcomes are (1) the composite of hospitalization for heart failure or cardiovascular death and (2) cardiovascular death.
Exploratory outcomes will be (1) regression of albuminuria, defined as change to normoalbuminuria in a patient with baseline microalbuminuria or macroalbuminuria or change to microalbuminuria in a patient with baseline macroalbuminuria, accompanied by a decrease in the urinary ACR value of ≥30% from baseline. A supplementary analysis of sustained regression will be performed that is restricted to events where regression is observed in duplicate assays; (2) Given the planned concordance in study design and patient population enrolled between the CANVAS-R and CANVAS studies, an integrated analysis will be performed to evaluate the cardiovascular safety and efficacy of canagliflozin using a closed testing procedure to control for type 1 error across the integrated analysis and CANVAS-R study at 5%. Safety data on acidosis, 14 malignancies, fatal pancreatitis, pancreatitis, severe hypersensitivity reactions, photosensitivity reactions, hepatic injury, acute kidney injury, venous thromboembolic events, fractures, male genital infections, amputation and pregnancy are also being systematically collected to provide better insight into the safety of the compound. The vascular safety events will all be reviewed by an Independent Endpoint Adjudication Committee, in addition to all other deaths, fractures, ESRD events and hospitalization for heart failure.
| Statistical power
Based on the interim data from the canagliflozin development programme, it was projected that the annual albuminuria progression rate for the CANVAS-R study will be~7.4% in the placebo arm. Assuming an 18-month accrual period, a minimum follow-up period of 18 months and an annual discontinuation (from treatment) rate of 10%, this was projected to provide >90% power (2-sided P = .05) to detect a 22% relative risk reduction for the primary outcome of albuminuria progression. This period of follow-up will also allow the accrual of sufficient major adverse cardiovascular events between this trial and CANVAS, such that the FDA post-marketing requirements can be met.
| Analysis
Analyses will be performed using the intention-to-treat population, and a P value of 0.05 will be taken to indicate a statistically significant effect. The primary efficacy analysis will seek to demonstrate the superiority of canagliflozin compared with placebo for the prevention of albuminuria progression. The time from randomization to the first visit date at which progression of albuminuria is recorded will be analysed using a Cox proportional hazards regression model. Appropriate correction will be made for regression to the mean. The model will include treatment and baseline albuminuria status as covariates. The hazard ratio comparing canagliflozin and placebo will be estimated with its 95% confidence interval. For participants who do not experience progression of albuminuria, censoring will be the visit date of the last albuminuria measurement. The cumulative progression rate derived from the Kaplan-Meier estimate will be displayed graphically to illustrate the timing of progression and to explore the consistency of the treatment effect over time.
The secondary efficacy analyses will use Cox proportional hazards models. A closed testing procedure will be implemented to control for the overall type 1 error at 5% for the primary and secondary endpoints across CANVAS-R and CANVAS with the hypotheses for the primary and secondary endpoints in CANVAS-R tested sequentially as part of a testing family. There are no interim analyses planned. The mean age of the participants at baseline was 64 years and 37% were women ( 
| Trial management
| DISCUSSION
The CANVAS-R trial has successfully randomized 5811 individuals with T2DM. The characteristics of the participants are typical of those of a high-risk population with diabetes, both in terms of the nature of the complications reported and the types of treatments that they are receiving. The proportion of participants with a history of atherosclerotic vascular disease is higher than is typically observed in this patient group but this reflects the inclusion criteria that targeted the enrolment of individuals with ischaemic macrovascular complications. The CANVAS-R population characteristics are directly comparable with those of the ongoing CANVAS trial, 11 which will ensure that a robust assessment of effects on cardiovascular and other outcomes can be made across the integrated data from the twin studies. Individuals with these characteristics are at a substantially elevated risk of both cardiovascular and renal complications, The exploration of canagliflozin as a novel strategy for the prevention of the renal complications of diabetes is based on strong preliminary data. SGLT2 inhibitors have been shown to lower glucose, blood pressure and body weight. 12, 15 Initial data from a subset of participants in the canagliflozin development programme that were available at the time of study design suggested protection against albuminuria, with mean changes in the ACR of +28 mg/g for placebo, −22 mg/g for canagliflozin 100 mg and −41 mg/g for canagliflozin 300 mg. 16 The mechanism of the glucose lowering based on tubular wasting of glucose is well understood and a plausible explanation of the antihypertensive effect is sodium excretion resulting from the inhibition of the joint sodium glucose co-transporter. 13 The mechanism of the albuminuria reduction remains to be determined. Possibilities include reduction in intraglomerular pressure induced by glomerular tubular feedback or atrial natriuretic peptide, modification of tubular albumin reabsorption, changes in the glycocalyx or reduced filtration as a result of reduction in eGFR. 17, 18 The change in albuminuria class selected as the primary outcome for CANVAS-R has been used in multiple previous renal out- In addition to the renal outcomes, the EMPA-REG OUTCOME trial also showed positive findings for cardiovascular outcomes, with particularly large benefits observed for vascular death and heart failure. 10 Confirmation of these findings as a class effect for SGLT2 inhibitors is urgently required and these outcomes have been defined as secondary outcomes for the CANVAS-R trial in a protocol update. As for the other CANVAS-R outcomes, there will be a parallel evaluation of the efficacy effects across the integrated data from the twin CANVAS-R and CANVAS studies in order to maximize statistical power.
Several recent concerns have been raised regarding potential adverse effects of SGLT2 inhibitors, and better safety data are required. Most recently, an elevated risk of amputation was reported by the data monitoring committee of CANVAS, 11 and the EMA is now seeking data about this outcome for all registered drugs in the SGLT2 class. 23 Diabetic ketoacidosis has also been noted as an uncommon, but serious, side effect of SGLT2 inhibitors, 14 and a possible increased risk of fracture has also been identified for canagliflozin 24 and in patients with moderate renal impairment treated with dapagliflozin. 25 While the absolute risk of serious side effects appears to be small, and the IDMC for the trials has recommended continuation, these observations provide a further imperative to quantify fully the overall impact of SGLT2 inhibition on all important outcomes. Only with data from largescale trials, such as CANVAS-R, will a robust estimate of the overall balance of risks and benefits be obtained. Future studies that include, for example, serial imaging of the heart might provide helpful additional insight into the mechanism of the macrovascular protection afforded. Likewise, retinal imaging studies would reveal whether protective effects on the renal microvasculature are mirrored elsewhere.
The ongoing large renal/cardiovascular outcome trials for canagliflozin will deliver substantial new data and will provide patients and FIGURE 2 CONSORT diagram. ALT, alanine aminotransferase; CV, cardiovascular; T1DM, type 1 diabetes mellitus; DKA, diabetic ketoacidosis. *One subject who was randomized twice in error has been excluded from follow-up and will be excluded from analysis.
